/ Zydus Starts Phase II Trial Of Zyan1 For Treating Anaemia ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Wednesday, 5 July 2017

Zydus has commenced the Phase II trial of Zyan1, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), as a treatment for anaemia associated with chronic kidney disease (CKD), the company said in a BSE filing on Wednesday.

Zyan1 is an oral small molecule that has been designed to inhibit hypoxia-inducible factor prolyl hydroxylase and thereby increase the natural production of haemoglobin and RBCs in anaemic patients. Zyan1 has been shown to improve iron mobilisation and has the potential to reduce or eliminate the need for iron supplementation.

Cadila Healthcare was trading at Rs 517.25, up by Rs 2.55 or 0.50% as at 1138 hours on Wednesday, on the BSE. 

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717